DOC

Business profile & competitive position

Healthpeak Properties, Inc. (NYSE: DOC) is an S&P 500, self-administered UPREIT operating under the Real Estate sector in the REIT – Healthcare Facilities industry. Through its operating subsidiary, Healthpeak OP, it owns, operates, and develops U.S. real estate tied to healthcare discovery and delivery. As of December 31, 2025, its portfolio carried interests in 689 properties: 507 outpatient medical buildings, 145 lab/life science buildings, 34 senior housing communities, plus three non-reportable properties and other investments such as loans receivable and a preferred equity position.

The competitive profile that emerges from the numbers is one of sticky, credit-anchored real estate rather than high-turnover operating leverage. Outpatient medical buildings were roughly 79% located on or adjacent to hospital campuses, about 96% affiliated with hospital systems, and approximately 72% triple-net leased by leased square feet; the segment also includes nine triple-net leased hospitals. Lab properties were approximately 89% triple-net leased by leased square feet and geographically concentrated in San Francisco (59%), Boston (22%), and San Diego (17%) by square feet. These figures point to a portfolio positioned around long-lease, tenant-credit, and cluster-density advantages rather than pure rental-rate growth.

The financial footprint, however, is modest on an equity-return basis. The company’s net margin is 8.6% and ROE is 3.3%. That 3.3% ROE is low relative to many broader-equity benchmarks and suggests capital intensity, depreciation-heavy accounting, and significant asset values relative to net income. REITs are often analyzed through funds from operations (FFO) and net operating income (NOI) rather than net income alone, but the reported equity-return figure is still a useful reality check: Healthpeak’s “moat” looks more like durable cash-flow stability backed by healthcare-anchored tenants than outsized profitability on a GAAP basis.

Financial posture

Healthpeak currently carries a $14.2 billion market capitalization and trades at a P/E multiple of 59.0. Net margin is 8.6% and ROE is 3.3%, while beta sits at 0.99, meaning the stock has historically moved roughly in line with the broader market. The gap between a 59.0 P/E and a 3.3% ROE is striking: it implies the market is pricing in long-term portfolio growth, recovery in lab/life-science demand, and/or dividend sustainability rather than current earnings power on a traditional ROE basis.

At $20.65, the stock’s RSI is 40.9 and its 50-day EMA is $21.04, so price is sitting just under a widely watched short-term moving average. The beta near 1.0 tells investors not to expect significant defensive cushioning relative to the S&P 500, even though healthcare real estate sounds defensive. The valuation also means there is little room for disappointment: when the earnings multiple is this elevated against a 3.3% ROE, forward expectations embedded in the price can be more demanding than the recent earnings trajectory suggests.

Strategic priorities & outlook

According to its most recent SEC 10-K filing, Healthpeak’s operational priorities center on owning, operating, and developing high-quality outpatient medical, lab, and senior housing real estate while managing the portfolio for long-term risk-adjusted returns and dividend growth. The company emphasizes maintaining a strong investment-grade balance sheet with ample liquidity and primarily long-term fixed-rate debt with staggered maturities, a structure designed to limit interest-rate and refinancing risk.

Internal growth is expected to come from working directly with tenants on space and capital needs, replacing tenants at favorable terms, extending or modifying leases prior to expiration, and providing high-quality property management to encourage renewals, expansions, and relocations. A near-term strategic milestone is the proposed Janus Living IPO in the first half of 2026, under which Healthpeak would contribute its 34-community senior housing portfolio, retain a substantial majority ownership interest, and serve as external manager.

In terms of reported segment economics for 2025, outpatient medical produced $795.8 million in Adjusted NOI, lab produced $567.4 million, and senior housing produced $176.7 million. By NOI contribution, outpatient medical and lab science are the dominant drivers. In January 2026, Healthpeak acquired the remaining 46.5% interest in its SWF SH JV, bringing its ownership of those 19 senior housing properties to 100% and signaling continued strategic activity in that segment ahead of the Janus transaction.

Macro & geopolitical exposure

As a healthcare REIT, Healthpeak sits at the intersection of real estate cyclicality and healthcare policy. The sector is exposed to interest-rate movements through both cap-rate valuation changes and debt-service costs, even though the company’s 10-K notes an effort to limit refinancing risk with long-term fixed-rate debt. Changes in Medicare and Medicaid reimbursement policy, CMS regulation, and broader healthcare-funding legislation can indirectly affect tenant credit quality and demand for medical space.

The lab/life-science piece adds exposure to biotech capital markets, venture-funding cycles, NIH grant flows, and tenant R&D budgets. Geographic clustering in San Francisco, Boston, and San Diego concentrates that risk in markets that are sensitive to technology and life-science employment trends, local zoning and permitting, seismic regulation, and rent-control debates. Construction costs, building materials, and skilled-labor availability affect development margins. Currency and direct overseas trade exposure are limited because the portfolio is U.S.-focused, but domestic supply-chain and tariff pressures can still feed into build-out costs and capital expenditures.

Recent developments

Recent news flow has mixed price action with institutional visibility. On September 3, 2026, Zacks published “Why Is Healthpeak (DOC) Down 3.5% Since Last Earnings Report?,” flagging that the stock had given back ground after its early-August release. Two days earlier, on September 1, 2026, GlobeNewswire reported that President and CEO Scott Brinker was interviewed by Advisor Access, giving management a platform to discuss strategy and performance.

On August 28, 2026, Zacks ran “DOC vs. EGP: Which Stock Is the Better Value Option?,” placing Healthpeak in a relative-valuation comparison. On August 27, 2026, DefenseWorld.net reported that Adelante Capital Management LLC bought 1,009,623 shares, indicating at least one institutional buyer was adding exposure around current levels. Altogether, the headline picture shows a name under recent price pressure, with active investor-selection and management-communication narratives running in parallel.

Earnings behavior & post-earnings drift

Healthpeak’s earnings history over the last eight reported quarters shows a 50% beat rate (4 beats out of 8) and an average earnings surprise of 18.2%. The average 5-day price move after earnings across those quarters is 2.24% to the upside, classified as an “up” drift. Those headline averages, however, mask a more nuanced story: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise.

The most recent four quarters illustrate that disconnect. For the August 4, 2026 quarter, DOC reported EPS of $0.08 against an estimate of $0.02815, a 184.2% positive surprise, yet the stock rose only 0.79% the next day and then fell 5.13% over the following five trading sessions. The May 5, 2026 quarter was the outlier: actual EPS of $0.28 versus an estimate of $0.05276 produced a 430.7% surprise, and the stock jumped 18.11% the next day and 19.81% over five days. By contrast, the February 2, 2026 miss—actual EPS $0.16 versus estimate $0.45, a negative 64.4% surprise—produced a next-day drop of 2.78% and a five-day drift of just minus 0.47%. The October 23, 2025 miss was more severe: actual EPS was negative $0.17 versus an estimate of $0.06, a negative 383.3% surprise, yet the stock actually rose 1.19% the next day before falling 5.23% over the following five days.

The next scheduled report is October 22, 2026 after the market close, with the consensus EPS estimate at $0.05355. That estimate represents the market’s real expectation heading into the print. The pattern to watch is not just whether DOC beats or misses, but how the market chooses to price the result over the subsequent week—the post-earnings record shows that beats can fade and misses can be initially shrugged off.

For a deeper dive into how institutional analysts are interpreting Healthpeak’s valuation setup, the Janus Living IPO timeline, and the upcoming October 22 earnings report, consider reviewing the full institutional verdict and consensus model rather than relying on headline figures alone.